AtriCure, Inc. (ATRC)
NASDAQ: ATRC · IEX Real-Time Price · USD
23.92
+0.55 (2.35%)
Apr 30, 2024, 1:53 PM EDT - Market open
AtriCure Revenue
In the year 2023, AtriCure had annual revenue of $399.25M with 20.84% growth. Revenue in the quarter ending December 31, 2023 was $106.54M with 21.03% year-over-year growth.
Revenue (ttm)
$399.25M
Revenue Growth
+20.84%
P/S Ratio
2.83
Revenue / Employee
$380,233
Employees
1,050
Market Cap
1.16B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.25M | 68.87M | 20.84% |
Dec 31, 2022 | 330.38M | 56.05M | 20.43% |
Dec 31, 2021 | 274.33M | 67.80M | 32.83% |
Dec 31, 2020 | 206.53M | -24.28M | -10.52% |
Dec 31, 2019 | 230.81M | 29.18M | 14.47% |
Dec 31, 2018 | 201.63M | 26.91M | 15.40% |
Dec 31, 2017 | 174.72M | 19.61M | 12.64% |
Dec 31, 2016 | 155.11M | 25.35M | 19.54% |
Dec 31, 2015 | 129.76M | 22.30M | 20.75% |
Dec 31, 2014 | 107.45M | 25.57M | 31.22% |
Dec 31, 2013 | 81.89M | 11.64M | 16.57% |
Dec 31, 2012 | 70.25M | 5.85M | 9.08% |
Dec 31, 2011 | 64.40M | 5.40M | 9.14% |
Dec 31, 2010 | 59.01M | 4.47M | 8.20% |
Dec 31, 2009 | 54.53M | -723.47K | -1.31% |
Dec 31, 2008 | 55.26M | 6.95M | 14.38% |
Dec 31, 2007 | 48.31M | 10.07M | 26.32% |
Dec 31, 2006 | 38.24M | 7.29M | 23.54% |
Dec 31, 2005 | 30.96M | 11.80M | 61.60% |
Dec 31, 2004 | 19.16M | 9.36M | 95.63% |
Dec 31, 2003 | 9.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Phreesia | 356.30M |
Maravai LifeSciences Holdings | 288.95M |
MannKind | 198.96M |
Mirum Pharmaceuticals | 186.37M |
Prothena Corporation | 91.37M |
Vir Biotechnology | 86.18M |
Immatics | 60.00M |
AbCellera Biologics | 38.03M |
ATRC News
- 6 hours ago - AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference - Business Wire
- 12 days ago - AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management - Business Wire
- 20 days ago - AtriCure to Announce First Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Business Wire
- 2 months ago - AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results - Business Wire
- 3 months ago - AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference - Business Wire
- 4 months ago - AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024 - Business Wire
- 4 months ago - AtriCure Appoints Shlomi Nachman to the Board of Directors - Business Wire